Merck & Company, Inc. vs Moderna, Inc. — Stock Comparison
Merck & Company, Inc. (MRK) and Moderna, Inc. (MRNA) are both listed on US exchanges. This page compares their Q·Score ratings, key fundamentals (P/E, margins, growth), and Wall Street analyst consensus side by side. Data sourced from Yahoo Finance and updated on each page load.
Merck & Company, Inc. clearly outscores Moderna, Inc. on Q·Score (6.3 vs 4.3 out of 10), led by Valuation (6.5 vs 1.9) and Quality (4.9 vs 1). Moderna, Inc. scores higher on Health, reflecting stronger balance sheet strength. Analyst consensus targets imply greater upside for MRK (-1.9%) than for MRNA (-31.1%).
Price Performance
Normalised to 100 at period start — shows relative performance.
Q·Score Breakdown
71% of 28 covering analysts have a positive rating.
⚠ weak profitability metrics drag quality score.
Clean balance sheet with low leverage (0.2× debt-to-equity).
⚠ currently unprofitable (-141% margin).
Analyst Consensus
Fundamentals
Frequently Asked Questions
MRK vs MRNA: which stock scores better overall?
Based on Q·Score, Merck & Company, Inc. (MRK) scores 6.3/10 versus Moderna, Inc. (MRNA) at 4.3/10. The Q·Score measures five dimensions: Quality, Health, Growth, Valuation, and Sentiment. For informational purposes only — not financial advice.
Which has better revenue growth: MRK or MRNA?
Merck & Company, Inc. (MRK) scores higher on Growth (6.4/10 vs 6.1/10). Merck & Company, Inc. reports revenue growth (5.1% YoY) while Moderna, Inc. reports (2.1% YoY). Growth scores reflect revenue and earnings momentum relative to sector peers.
Is MRK or MRNA more attractively valued?
Merck & Company, Inc. (MRK) scores higher on Valuation (6.5/10 vs 1.9/10). Valuation is assessed using P/E ratio, analyst price targets, and 52-week range positioning relative to sector peers.
What do analysts say about MRK vs MRNA?
There are 26 analysts covering MRK with a consensus price target of $147.77, and 18 analysts covering MRNA with a consensus target of $95.67. Analyst consensus ratings are aggregated from Wall Street research and do not constitute investment advice.
Which is more profitable: MRK or MRNA?
Merck & Company, Inc. (MRK) scores higher on Quality (4.9/10 vs 1/10). Net profit margin: MRK at 4.8%, MRNA at -141.4%. Quality scores reflect profit margins, return on equity, and free cash flow generation.
Which has stronger financial health: MRK or MRNA?
Moderna, Inc. (MRNA) scores higher on Financial Health (9.4/10 vs 7/10). Market beta: MRK at 0.21, MRNA at 0.90. Health scores consider beta, debt-to-equity, and current ratio. All investments carry risk — this is not investment advice.
What are the market caps of MRK and MRNA?
Merck & Company, Inc. (MRK) has a market capitalisation of $371.7B, while Moderna, Inc. (MRNA) has a market cap of $55.4B. Market cap data is sourced from Yahoo Finance and reflects the most recent available figures.
Do MRK or MRNA pay dividends?
MRK pays a dividend yield of 2.26%, while MRNA does not currently pay a dividend. Dividend yields fluctuate with share price and company payout decisions.
Related Comparisons
Q·Score is an educational tool and is not financial advice. Data provided by Yahoo Finance. Updated on each page load. How it's calculated →